Key result
Rising OxPL-PLG linked to native heart survival in tMCS-treated cardiogenic shock.
Why the study?
Cardiogenic shock is characterized by oxidative stress and thrombo-inflammatory dysregulation despite temporary mechanical circulatory support (tMCS), but whether oxidized phospholipids (OxPL) are pathophysiologically involved and whether longitudinal changes in OxPL carriers and plasminogen are associated with native heart survival in tMCS-treated CS remained unknown.
Are longitudinal increases in oxidized phospholipids bound to plasminogen (OxPL-PLG) associated with native heart survival to discharge in adults with temporary mechanical circulatory support-treated cardiogenic shock?
Cohort (n=70)
No
Are longitudinal increases in oxidized phospholipids bound to plasminogen (OxPL-PLG) associated with native heart survival to discharge in adults with temporary mechanical circulatory support-treated cardiogenic shock?
In patients with cardiogenic shock treated with temporary mechanical circulatory support, serial increases in oxidized phospholipids bound to plasminogen (OxPL-PLG) are specifically associated with native heart survival to hospital discharge.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for OxPL-PLG monitoring in tMCS-treated shock; should not yet change practice.
Background Oxidized phospholipids (OxPL) bind to circulating proteins, including plasminogen, apoB, and apo(a), with carrier-specific biological effects. While OxPL on apoB/apo(a) are linked to atherothrombosis, OxPL bound to plasminogen (OxPL-PLG) mediate faster fibrinolysis ex vivo and have been associated with lower risk of type I myocardial infarction and major cardiovascular events in human studies. Cardiogenic shock (CS) is characterized by oxidative stress and thrombo-inflammatory dysregulation that may persist despite temporary mechanical circulatory support (tMCS). Whether OxPL are pathophysiologically involved in CS remains unknown. Purpose To determine whether longitudinal changes in OxPL carriers and plasminogen are associated with native heart survival (NHS) in tMCS-treated CS. Methods Serial plasma samples (pre-tMCS, explant, discharge) were analyzed in 70 adults with tMCS-treated CS enrolled in a prospective registry. OxPL-PLG (primary biomarker), total plasminogen, OxPL-apoB, and OxPL-apo(a) were quantified by validated ELISAs. NHS was defined as survival to discharge without cardiac replacement therapy (NHS n=33; no NHS n=37 [death n=26, durable LVAD n=6, heart transplantation n=5]). Linear mixed-effects models assessed within-patient trajectories over time, allowing patterns to differ by NHS status. Models adjusted for age, chronic heart failure (HF), SCAI stage, and VA ECMO use. Results Baseline demographics, shock etiology, clinical and hemodynamic severity, and tMCS modality were comparable between groups. Chronic HF (40.5% vs 18.2%, p=0.038), CKD stage III-IV (24.3% vs 3%, p=0.027), and valvular heart disease (27% vs 3%, p=0.004) were more prevalent without NHS. Baseline OxPL-PLG levels were similar (NHS: 216.6 [152.0-281.2] vs no NHS: 235.4 [174.3-296.4] nmol/L). Over time, trajectories diverged: NHS patients demonstrated progressive increases (216.6 [152.0-281.2]->289.2 [221.4-357.0]->483.6 [406.2-561.1], p<0.001), whereas no NHS patients showed attenuated changes (235.4 [174.3-296.4]->266.7 [200.1-333.4]->323.3 [233.3-413.4], p=0.11). The time-by-NHS interaction was significant (p=0.002) and consistent across adjusted models. OxPL-apoB and OxPL-apo(a) showed no longitudinal association with NHS. Total plasminogen was higher at discharge in NHS patients (10.9 [8.4-13.4] vs 3.9 [1.0-6.9], p<0.001) but similar at baseline. After inclusion of total plasminogen, the time-by-NHS interaction was attenuated and no longer statistically significant, although the trajectory difference remained directionally consistent with similar magnitude. Conclusions In tMCS-treated CS, serial increases in OxPL-PLG were associated with NHS. The absence of similar trajectories in other OxPL carriers supports a carrier-specific association. Whether OxPL-PLG-associated fibrinolytic activity contributes to NHS warrants further mechanistic and multicenter validation.
No takes yet. Share an insight, caveat, or question.
Taleb et al. (2026) conducted a cohort in Cardiogenic shock treated with temporary mechanical circulatory support (tMCS) (n=70). Longitudinal increases in oxidized phospholipids on plasminogen (OxPL-PLG) vs. No native heart survival (death, durable LVAD, or heart transplantation) was evaluated on Native heart survival (survival to discharge without cardiac replacement therapy) and longitudinal OxPL-PLG trajectory (p=0.002). Serial increases in OxPL-PLG were associated with native heart survival in tMCS-treated cardiogenic shock.
Synapse has enriched 10 related papers. Consider them for comparative context: